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Dear Editor,
Breast cancer (BC) is the most common cancer 
in women. A total of 252,710 new cases and 40610 
deaths from BC occurred in women in the United 
States in 2017. The risk of BC was 12.5% in the 
American women’s lifetime1. The pathway and 
risk factors for this cancer have not been fully di-
agnosed. Obesity and overweight, family history 
of BC, genetic factors, environmental factors, low 
physical activity, and exposure to chemical are 
among the diagnosed BC risk factors2,3. A lot of 
studies have been planned to identify substances 
with a chemopreventive potential against breast 
cancer. The pharmaceutical group of Statins is 
widely prescribed in the world with the aim to 
prevent cardiovascular events and stroke.
The protective effects of Statins have been 
proven against the onset of some cancers. How-
ever, controversial results4 have been observed in 
studies on the effects of Statins on the incidence 
of BC, so that some separate investigations have 
considered Statins as the protective agents5,6, as 
risk factors7-9 and neutral10. There is not any de-
finitive conclusion on the effects of Statins on the 
risk of BC. Undoubtedly, the results of meta-anal-
ysis studies can be helpful in this regard. Sever-
al meta-analysis researches on this field have not 
found any significant relationship between Statin 
use and the increase or decrease in the BC risk, so 
that the relative risk of BC in the treatment group 
compared to the control group was obtained equal 
to 0.94 (CI of 95%, 0.86-1.03) in the research by 
Islam et al11, equal to 1.02 (CI: 95%, 0.95-1.09) 
in research by Qi-Jun et al12, equal to 0.99 (CI 
of 95%, 0.94-1.04) in study by Undela et al4, and 
equal to 1.02 (CI of 95%, 0.89-1.18) in study by 
Bonova et al10. According to a research by Islam 
et al11, the relative risk of BC was equal to 0.94 (CI 
of 95%, 0.70-1.28) for those who received Statins 
for 5 years or less and equal to 0.74 (CI of 95%, 
0.52-1.04) for those who received Statins for over 
5 years11.
Furthermore, there was not any significant dif-
ference between Statins and the risk of BC in dif-
ferent parts of the world, so that the relative risk of 
BC in the treatment group compared to the control 
group was equal to 0.85 (CI of 95%, 0.41-1.52) in 
Asia, 1.01 (CI of 95%, 0.97-1.05) in Europe, 1.13 
(CI of 95%, 0.44-2.92) in Oceania, and 0.92 (CI of 
95%, 0.84-1.02) in the United States11. Therefore, 
based on the results of meta-analysis studies, which 
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provide the highest level of scientific inferences, 
the use of statin does not significantly increase or 
decrease the risk of BC in recipients. Furthermore, 
the incidence of BC does not depend on the dura-
tion of Statin use and the geographical area of resi-
dence. Consequently, statins can be used in preven-
tion of cardiovascular diseases and stroke without 
any worry about the increased risk of BC.
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